About ECCO
ECCO General Assembly
ECCO Governing Board
The Council of National Representatives
Solidarity for Ukraine
ECCO Operational Board / Committees
Committee Podcasts
Affiliate ECCO Societies & ECCO Partners
ECCO Office
ECCO Disclosures
ECCO Elections
Congresses & Events
Future
19th Congress of ECCO 2024 - Stockholm
Past
18th Congress of ECCO 2023 - Copenhagen
Event Calendar
Quality Assurance/Endorsement
Congress Statistics
Register
Membership
Individual Membership
Country Members
Corporate Membership
Affiliate ECCO Societies
Education
E-QUALITY
e-CCO Learning
Educational Workshops
Congress Educational Programme
IBD Nurse Education Programme
Y-ECCO Mentorship Forum
Letters from the e-Learning Ambassador
Science
UR-CARE
The Reviewers of ECCO
The Reviewers of 2022
Fellowships and Grants
ECCO Young Researcher Award
Scientific Workshops
Research Projects
BIOCYCLE Dissemination Workshops
ECCO CONFER Cases
Job postings
Publications
JCC
ECCO Guidelines
ECCO Topical Review
ECCO Position Statements
ECCO Scientific Workshop Papers
ECCO News
ECCO IBD App
ECCO Congress Abstracts
Surveys
Other publications
COVID-19
20years Anniversary Book
eNewsletter
Search
Author
Title
Category
Choose
Abstracts 2023
Abstracts 2022
Abstract 2021
Search
Clear
Scientific Session 8: IBD Horizons
OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12
OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 study
OP25 Patients with moderate to severe Crohn’s Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trials
OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
OP27 A Phase 1 Study Evaluating the Bioequivalence of the Proposed Commercial and Clinical Formulations of Etrasimod 2mg, and the Effect of Food on the Pharmacokinetics of the Proposed Commercial Formulation in Healthy Volunteers
OP28 A randomized placebo controlled clinical trial with 5-hydroxytryptophan in patients with quiescent Inflammatory Bowel Disease and fatigue (Trp-IBD)
About ECCO
ECCO General Assembly
ECCO Governing Board
The Council of National Representatives
Solidarity for Ukraine
ECCO Operational Board / Committees
Committee Podcasts
Affiliate ECCO Societies & ECCO Partners
ECCO Office
ECCO Disclosures
ECCO Elections
Congresses & Events
Future
19th Congress of ECCO 2024 - Stockholm
Past
18th Congress of ECCO 2023 - Copenhagen
Event Calendar
Quality Assurance/Endorsement
Congress Statistics
Register
Membership
Individual Membership
Country Members
Corporate Membership
Affiliate ECCO Societies
Education
E-QUALITY
e-CCO Learning
Educational Workshops
Congress Educational Programme
IBD Nurse Education Programme
Y-ECCO Mentorship Forum
Letters from the e-Learning Ambassador
Science
UR-CARE
The Reviewers of ECCO
The Reviewers of 2022
Fellowships and Grants
ECCO Young Researcher Award
Scientific Workshops
Research Projects
BIOCYCLE Dissemination Workshops
ECCO CONFER Cases
Job postings
Publications
JCC
ECCO Guidelines
ECCO Topical Review
ECCO Position Statements
ECCO Scientific Workshop Papers
ECCO News
ECCO IBD App
ECCO Congress Abstracts
Surveys
Other publications
COVID-19
20years Anniversary Book
eNewsletter